On August 4, 2022, the sixth China Biomedical Innovation and Cooperation Conference and the 2022 China Biomedical Industry Value List Award Ceremony officially opened, at which the 2022 China Biomedical Industry Value List was released. DeNuo Capital was awarded the "Top 10 Most Potential Investment Institutions in the Biomedical Industry". In addition, DeNuo Capital's investment enterprises Haichuang Pharmaceutical and Xuanzhu Bio were strongly listed in the "Top 10 Growth Molecular Innovative Pharmaceutical Enterprises".

Top 10 Most Potential Investment Institutions in Biomedical Industry: Denuo Capital

Top 10 small molecule innovative drug enterprises with the most growth potential: Haichuang Pharmaceutical, Xuanzhu Biology

The current China Biomedical Innovation Cooperation Conference was co sponsored by Wanyi Medicine and Beijing Medical Award Foundation; The Joint Conference Office of the Yangtze River Delta G60 Science and Innovation Corridor, the School of Pharmacy of Suzhou University, and the Xipu Huihu School of Pharmacy serve as the guiding units; BioBAY, Yiyun Science and Technology, Jiangsu Industrial Technology Research Institute, Yangtze River Delta Science and Technology Elements Trading Center, CUBIO, Meibai Medical Health, and the Pharmaceutical Association co sponsored it.

The conference focused on cutting-edge technology information, interpreted the latest industrial policies, and linked multiple platforms of industry, education, research and investment. Zhong, Wanyi Medical and Chinese Medical Research Institute conducted in-depth evaluation on industries, industries and enterprises from multiple dimensions such as strategic elements, product elements, competitive elements, team elements, commercialization elements, and value elements, and formed the "2022 China Biomedical Industry Value List" through evaluation processes such as collection, data revisit, and systematic research